Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Davidoff, F.
space
 arrow  PubMed                        
space

REPLY

Where's the Bias?

right arrow Frank Davidoff, MD

1 January 1998 | Volume 128 Issue 1 | Page 75


IN RESPONSE:

Dr. Gwaltney is certainly correct in stating that proper blinding is an important element in clinical trial design [1]. However, as they pointed out elsewhere, Mossad and colleagues were unable to demonstrate unblinding in the two study groups, despite conscientious efforts to do so [2]. Moreover, because there would be no way participants could know a priori what the active agent was supposed to taste like, it is difficult to see how tasting only a single type of lozenge would give participants in either group any meaningful basis for deciding whether the type assigned to them contained the "active" agent. They might have received some clue (however unreliable) if they had been able to compare the taste of the two lozenges, but they were not allowed to do so.

Mr. Eby raises an interesting physicochemical point in suggesting that some zinc preparations contain an excess of negatively charged chelating agents, such as citrate, which prevent zinc ions from local release and may bind native zinc and other divalent cations locally. At the same time, it is also possible that in the complex environment of an inflamed pharynx, the citrate is metabolized or displaced (for example, by negatively charged proteins, and by mass action of other anionic species, such as chloride), thus freeing up zinc locally. This problem is amenable to study.

The issue Dr. Hollister raises-that of "purity"-is generally kept at the periphery in discussions of bias but is really quite important. It is difficult, on the one hand, to argue with the moral imperative of staying "clean" when it comes to dealing with potential bias. On the other hand, there is a seemingly inevitable tendency, particularly for those of us who struggle publicly with conflict of interest, to become moralistic, to be drawn into a kind of snobbery about "who's the purest of them all" in these matters. The sin of pride, perhaps? In any event, Dr. Hollister is probably right that even we editors, generally the most modest of people, could use an additional touch of humility from time to time.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Editor


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995; 273:408-12.

2. Macknin ML, Mossad SB, Medendorp SV. Zinc gluconate lozenges for treating the common cold [Letter]. Ann Intern Med. 1997; 126:739.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
A. S. Prasad, J. T. Fitzgerald, B. Bao, F. W.J. Beck, and P. H. Chandrasekar
Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate: A Randomized, Double-Blind, Placebo-Controlled Trial
Ann Intern Med, August 15, 2000; 133(4): 245 - 252.
[Abstract] [Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Davidoff, F.
space
 arrow  PubMed                        
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online